Celera, Abbott To Seek Genetic Markers of Response to Abbott Compound | GenomeWeb
NEW YORK (GenomeWeb News) – Celera and Abbott are collaborating on a project to identify genetic markers for an undisclosed investigational compound under development at Abbott, Celera said today.
 
The partners plan to determine whether genetic variants Celera has identified can predict how patients may respond to treatment with the drug.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.